There are many valid reasons to push forward with legal reforms to advance psychedelic medicine. In the U.S., however, it is the treatment of PTSD that is bringing Republicans and Democrats together.
Big Pharma In Psychedelics: Inside Mindset Pharma’s Deal With Otsuka
How interested are pharmaceutical companies in psychedelics? While some are hesitant to even discuss where they stand on this restricted class of drugs, a deal inked last month validates the path of at least one company developing next-generation psychedelics.
Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety Disorders
Cybin announces receiving a composition of matter patent for its DMT-derived compound, CYB004 from the the USPTO.
Elemental Advisors Launches PSYK ETF Focused on the Medical Psychedelics Industry
A new U.S.-based psychedelics ETF will begin trading on the NYSE, symbol "PSYK".
Optimi Health Dealer’s License Granted by Health Canada
Optimi Health announces receiving its Dealer's License from Health Canada, allowing the possession, production and sale of psilocybin.
Awakn Life Sciences Receives Bold Price Target From H.C. Wainwright
This morning, Awakn Life Sciences Corp. became the latest psychedelic company to obtain coverage under the H.C. Wainwright umbrella.
Novamind Hosts Clinical Trial to Advance Ketamine Therapy for End-of-Life Patients
Novamind will host a Phase II clinical trial by the Ketamine Research Foundation for ketamine therapy for the terminally ill.
Amendments To Canada's Special Access Program (SAP) Allows Access To Restricted Psychedelic Drugs. How Will This Affect The Industry?
Mental health professionals have been exploring psychedelics as a treatment for substance abuse and mental health disorders for decades, and now its status as a legitimate treatment is being recognized in Canada.
Red Light Holland's Partner CCrest Laboratories Approved By Health Canada to Supply Psilocybin to the Special Access Program
Red Light Holland partner, CCrest Laboratories, has been approved by a Health Canada as a supplier of psilocybin for the SAP.
Has A Sugar Daddy Emerged In The Psychedelic Drug Industry?
As new deep pockets emerge to finance psychedelic drug development, we also learn that this R&D isn't as expensive as some drug companies claim.
Novamind Announces Closing of CAD$5 Million Private Placement with Institutional Investor
Novamind announces the closing of its previously announced CAD$5 million private placement.
atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments
atai launches Invyxis, as a new company devoted to the creation of novel psychedelics molecules.
